AbbVie (NYSE:ABBV) delivered a robust full-year performance for 2025, proving that its strategy to replace the aging blockbuster Humira is ahead of schedule as its newer immunology and neuroscience portfolios hit record highs.
Silicon Labs (NASDAQ:SLAB), a leader in secure, intelligent wireless technology for IoT applications, reported financial results for fiscal 2025 ended January 3, 2026.
Adient (NYSE:ADNT) reported first-quarter adjusted profits that handily beat Wall Street estimates, leading the automotive seating manufacturer to raise its financial outlook for the full fiscal year.
Eli Lilly (NYSE:LLY) delivered a blowout fourth-quarter report and a massive 2026 forecast that solidified its position as the world’s most valuable healthcare company, fueled by the explosive growth of its tirzepatide franchise.
Azenta (NASDAQ:AZT) shares fell Wednesday after the company reported first-quarter earnings that missed analyst estimates, as costs related to its ongoing business turnaround pressured profit margins.
Boston Scientific (NYSE:BSX) reported fourth-quarter results that topped analyst estimates, driven by a double-digit surge in its cardiovascular division and a string of regulatory wins that are reshaping its competitive landscape.
GE HealthCare Technologies (NASDAQ:GEHC) delivered a strong finish to 2025, reporting fourth-quarter sales that outpaced expectations and providing a 2026 forecast that signals continued margin expansion for the medical-tech giant.
MiNK Therapeutics (NASDAQ:INKT) unveiled new translational data at the Keystone Symposia on Wednesday, providing the first direct evidence in humans that a specific immune cell deficiency may be a primary driver of the scarring that defines idiopathic pulmonary fibrosis (IPF).
GSK (NYSE:GSK) reported fourth-quarter results that cleared Wall Street estimates, as the British drugmaker successfully leveraged its high-growth specialty medicines to offset slowing demand for its flagship RSV vaccine, Arexvy.
Novartis (NYSE:NVS) reported fourth-quarter adjusted earnings that beat analyst estimates on Wednesday, but the Swiss pharmaceutical giant issued a cautious 2026 outlook as it prepares to navigate the largest wave of patent expirations in its history.
Novo Nordisk (NYSE:NVO) reported fourth-quarter results on Wednesday that exceeded analyst expectations, but shares plummeted as the Danish pharmaceutical giant issued a "shocking" outlook for 2026, warning of a potential double-digit decline in sales and profit.
Mesa Laboratories (NASDAQ:MLAB) reported a sharp increase in profitability for its third fiscal quarter, as strong demand for its biopharmaceutical tools more than offset a collapse in its Chinese diagnostic business.
